The notices it replaced
- Reissues: RFA-OD-22-009 Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)
- 2 steps back: RFA-OD-20-005 Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)
- 3 steps back: RFA-OD-19-016 Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)
Who won it before
47 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $94,550,301 in first-year total cost, median $1,959,062.
Most frequent study sections
- Special Emphasis Panel[ZRG1 VH-A (90)]17
- Special Emphasis Panel[ZRG1 IVBH-B (57)]7
- Special Emphasis Panel[ZRG1 BST-J (50)]6
- Special Emphasis Panel[ZRG1 BST-L (51)]6
- Special Emphasis Panel[ZRG1 BST-W (55)]6
Most frequent institutions
- UNIVERSITY OF COLORADO DENVER10
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI3
- INDIANA UNIVERSITY INDIANAPOLIS2
- TEXAS A&M AGRILIFE RESEARCH2
- UNIVERSITY OF CALIFORNIA, SAN DIEGO2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Modifiers of Down Syndrome Co-occurring Phenotypes1R01HD118475-01 · under RFA-OD-22-009 | ROPER, RANDALL J | INDIANA UNIVERSITY INDIANAPOLIS, IN | $1,303,054 | ZRG1 |
| 2025 | Transposable Element Mobilization and Disrupted Translational Machinery in Down Syndrome1RF1NS142871-01 · under RFA-OD-22-009 | KALISH, BRIAN | BOSTON CHILDREN'S HOSPITAL, MA | $1,274,904 | ZRG1 |
| 2025 | A humanized monoclonal FSH antibody for Alzheimer's Disease and co-occurring health conditions in Down Syndrome1R01AG093773-01 · under RFA-OD-22-009 | GOOSENS, KI ANNZAIDI, MONE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $1,257,163 | ZRG1 |
| 2025 | Allelic Expression Imbalance in Trisomy 211RF1NS142814-01 · under RFA-OD-22-009 | THAYER, MATHEW J | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $780,000 | ZRG1 |
| 2024 | The role of immune deregulation and NGF dysmetabolism in the development of Alzheimer disease in individuals with Down syndrome1R01AG087280-01 · under RFA-OD-22-009 | BUSCIGLIO, JORGE ACUELLO, A CLAUDIOFORTEA, JUANWISNIEWSKI, THOMAS M | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $1,105,775 | ZRG1 |
| 2024 | Multidimensional investigation of auditory dysfunction in Down syndrome1R01DC021819-01 · under RFA-OD-22-009 | ESPINOSA, JOAQUIN M.MERCHANT, GABRIELLE RYANSTEYGER, PETER STEPHEN | UNIVERSITY OF COLORADO DENVER, CO | $942,771 | ZRG1 |
| 2024 | Large-scale Genetic Investigation and Drug Discovery to Counteract Down Syndrome Neural Deficits1R01HD115159-01 · under RFA-OD-22-009 | THYME, SUMMER B | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $826,661 | ZRG1 |
| 2024 | Preventing Fatal Infections in Children with Down Syndrome During Treatment for Acute Lymphoblastic Leukemia1R01CA290539-01 · under RFA-OD-22-009 | GUIDOS, CYNTHIA J.RABIN, KAREN RRYEOM, SANDRA | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $548,211 | ZRG1 |
| 2024 | Molecular regulators of GABAergic systems that underlie comorbidities in Down syndrome1R01NS137222-01 · under RFA-OD-22-009 | DIERSSEN, MARAVALERO GARCIA, MANUELYE, BING | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $458,523 | ZRG1 |
| 2024 | Intrinsic and Extrinsic Factors Contributing to Trisomy 21 Preleukemia1R01CA290681-01 · under RFA-OD-22-009 | WAGENBLAST, ELVIN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $426,919 | ZRG1 |
| 2024 | Enhancing treatments for myeloid leukemia associated with Down syndrome1R01CA290480-01 · under RFA-OD-22-009 | GE, YUBINTAUB, JEFFREY WARREN | WAYNE STATE UNIVERSITY, MI | $306,623 | ZRG1 |
| 2023 | A heterochronic model for birth defects in Down Syndrome1R01HD111938-01 · under RFA-OD-22-009 | MOSKOWITZ, IVAN PAUL | UNIVERSITY OF CHICAGO, IL | $5,035,031 | ZRG1 |
| 2023 | Defining the Role of Enteric Nervous System Dysfunction in Gastrointestinal Motor and Sensory Abnormalities in Down Syndrome1RF1NS128738-01A1 · under RFA-OD-22-009 | BELKIND-GERSON, JAIMEFRANK, DANIEL NSULLIVAN, KELLY D. | UNIVERSITY OF COLORADO DENVER, CO | $2,837,478 | ZRG1 |
| 2023 | Investigating and targeting apolipoprotein E4 in Down syndrome-associated Alzheimer's disease1RF1AG078965-01A1 · under RFA-OD-22-009 | JOHNSON, NOAH RAY | UNIVERSITY OF COLORADO DENVER, CO | $2,282,487 | ZRG1 |
| 2023 | A mosaic Down syndrome model system comparing isogenic trisomic/disomic cells to unmask trisomy-21 related genomic, epigenomic, and senescence changes acquired across the lifespan1R01HD111943-01 · under RFA-OD-22-009 | JACKSON-COOK, COLLEEN K | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $2,217,370 | ZRG1 |
| 2023 | Investigating epigenetic mechanisms in Down syndrome using human cellular models1R01HD111876-01 · under RFA-OD-22-009 | BARRETT, LINDY ELISE | BROAD INSTITUTE, INC., MA | $2,034,753 | ZRG1 |
| 2023 | SIM2 Regulation of Mitochondrial Dysfunction in Down Syndrome1R01HD111848-01 · under RFA-OD-22-009 | PORTER, WESTON W | TEXAS A&M AGRILIFE RESEARCH, TX | $1,960,246 | ZRG1 |
| 2023 | A Physiologically Integrated Approach to Studying Mechanisms of Speech Production and Swallow Function in Down Syndrome1R01DC020622-01A1 · under RFA-OD-22-009 | WILKINSON, KRISTA M | PENNSYLVANIA STATE UNIVERSITY, THE, PA | $1,959,062 | ZRG1 |
| 2023 | Determining cell-specific mechanisms that drive aberrant bone regeneration in Down syndrome1RF1AG081812-01 · under RFA-OD-22-009 | DAWSON, LINDSAY A | TEXAS A&M AGRILIFE RESEARCH, TX | $1,633,451 | ZRG1 |
| 2023 | Molecular mechanisms of oral deficiencies in Down syndrome1R01DE032846-01 · under RFA-OD-22-009 | LACRUZ, RODRIGO S. | NEW YORK UNIVERSITY, NY | $1,513,264 | ZRG1 |
| 2023 | Investigating the Mechanism of Optic Nerve disorders associated with Down Syndrome1R01EY033141-01A1 · under RFA-OD-22-009 | MUKHERJEE, KONARK | VIRGINIA POLYTECHNIC INST AND ST UNIV, VA | $1 | ZRG1 |
| 2022 | Neurovascular unit dysfunction in Down syndrome revealed by TBI1RF1NS128739-01 · under RFA-OD-20-005 | HUANG, MINGXIAPOTTER, HUNTINGTONSULLIVAN, KELLY D. | UNIVERSITY OF COLORADO DENVER, CO | $2,601,812 | ZRG1 |
| 2022 | Why do Down Syndrome patients have high risk of Hirschsprung disease?1R01DK135089-01 · under RFA-OD-20-005 | CHAKRAVARTI, ARAVINDACHATTERJEE, SUMANTRADAVOLI, TERESA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $2,486,641 | ZRG1 |
| 2022 | Novel computational strategies to deconvolute co-occurring conditions in Down syndrome1R01HD109765-01 · under RFA-OD-20-005 | COSTELLO, JAMES CHRISTOPHERGREENE, CASEY S | UNIVERSITY OF COLORADO DENVER, CO | $2,353,137 | ZRG1 |
| 2022 | The role of APP in neurogenesis and AD in Down syndrome1RF1AG079002-01 · under RFA-OD-20-005 | LAZAROV, ORLY | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $2,005,131 | ZRG1 |
| 2022 | Restoration of proteostasis to address co-occurring conditions in Down Syndrome1RF1AG078969-01 · under RFA-OD-20-005 | NAIDOO, NIRMALA NIRINJINI | UNIVERSITY OF PENNSYLVANIA, PA | $1,856,328 | ZRG1 |
| 2022 | Down Syndrome: a potential treatment XISTs1R01HD109794-01 · under RFA-OD-20-005 | SHEEN, VOLNEY L | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $1,693,316 | ZRG1 |
| 2022 | Generation and analysis of new mouse models to determine novel therapeutic targets for Down syndrome-associated cognitive deficits1R01HD109750-01 · under RFA-OD-20-005 | YU, EUGENE | ROSWELL PARK CANCER INSTITUTE CORP, NY | $475,839 | ZRG1 |
| 2021 | Human cortical development and neural plasticity altered by trisomy 211R01HD106197-01 · under RFA-OD-20-005 | BHATTACHARYYA, ANITAZHANG, SU-CHUN | UNIVERSITY OF WISCONSIN-MADISON, WI | $7,005,920 | ZRG1 |
| 2021 | Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome1RF1AG073979-01 · under RFA-OD-20-005 | RAFII, MICHAEL SRISSMAN, ROBERT | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $2,328,791 | ZRG1 |
| 2021 | Emulating Immune Dysregulation by Trisomy 21 in a Multi-Organ-on-a-Chip System1R01HL159494-01 · under RFA-OD-20-005 | HAJIPOURAN BENAM, KAMBEZ | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $2,101,852 | ZRG1 |
| 2021 | A Human iPSC-Based Chimeric Mouse Model of Alzheimers Disease in Down Syndrome1R01AG073779-01 · under RFA-OD-20-005 | JIANG, PENG | RUTGERS, THE STATE UNIV OF N.J., NJ | $2,008,397 | ZRG1 |
| 2021 | Defining the Role of DNA Rereplication of Chromosome 21 in the Development and Pathophysiology of Down Syndrome1R01AI155918-01 · under RFA-OD-20-005 | BLACK, JOSHUA CRANSTONSULLIVAN, KELLY D. | UNIVERSITY OF COLORADO DENVER, CO | $1,918,500 | ZRG1 |
| 2021 | Molecular mechanism of dysregulated airway antiviral responses in children with Trisomy 211R01HL159595-01 · under RFA-OD-20-005 | JAISWAL, JYOTI KNINO, GUSTAVO | CHILDREN'S RESEARCH INSTITUTE, DC | $1,643,687 | ZRG1 |
| 2021 | New Down syndrome brain organization revealed by single-cell genomics1R56AG073965-01 · under RFA-OD-20-005 | CHUN, JEROLD | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $1,395,349 | ZRG1 |
| 2021 | Targeting protein synthesis dysregulation in Down syndrome-associated cognitive impairment with aging1R01AG073823-01 · under RFA-OD-20-005 | MA, TAO | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $1,142,664 | ZRG1 |
| 2020 | Multiplexed Single Nucleus RNA and ATAC-seq Sequencing and Cortical Organoids: Transformative Insights into Down Syndrome1R01AG070154-01 · under RFA-OD-20-005 | MOBLEY, WILLIAM CROSENFELD, MICHAEL G | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $5,047,008 | ZRG1 |
| 2020 | Characterizing Innate Immune Dysregulation in Tonsils of Individuals with Down Syndrome1R01HL155691-01 · under RFA-OD-20-005 | VERNERIS, MICHAEL R. | UNIVERSITY OF COLORADO DENVER, CO | $3,038,439 | ZRG1 |
| 2020 | Down Syndrome as a systemic autophagy deficiency disorder1R01HD103828-01 · under RFA-OD-20-005 | DEGREGORI, JAMES VTHORBURN, ANDREW M | UNIVERSITY OF COLORADO DENVER, CO | $2,594,673 | ZRG1 |
| 2020 | Strategies for treatment of Down syndrome: Identifying age- and sex-specific developmental windows using inducible genetic reduction of Dyrk1a1R01AR078663-01 · under RFA-OD-20-005 | GOODLETT, CHARLES R.ROPER, RANDALL J | INDIANA UNIVERSITY INDIANAPOLIS, IN | $1,919,804 | ZRG1 |
| 2020 | Noradrenergic dysfunction in Down Syndrome1RF1AG070153-01 · under RFA-OD-20-005 | LEDREUX, AURÉLIE | UNIVERSITY OF DENVER (COLORADO SEMINARY), CO | $264,005 | ZRG1 |
| 2019 | Molecular Causes of Down Syndrome Associated Congenital Heart Disease and Other Phenotypes1R01HL151257-01 · under RFA-OD-19-016 | SEIDMAN, JONATHAN G | HARVARD MEDICAL SCHOOL, MA | $3,724,305 | ZRG1 |
| 2019 | Understanding the complexity of gene dosage imbalance in Down syndrome1R01HL151260-01 · under RFA-OD-19-016 | CHOU, STELLA T | CHILDREN'S HOSP OF PHILADELPHIA, PA | $3,352,210 | ZRG1 |
| 2019 | Type I Interferon Dysregulation in Down Syndrome1R01AI150300-01 · under RFA-OD-19-016 | BOGUNOVIC, DUSAN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $3,207,900 | ZRG1 |
| 2019 | Understanding Down Syndrome as an Interferonopathy1R01AI150305-01 · under RFA-OD-19-016 | ESPINOSA, JOAQUIN M. | UNIVERSITY OF COLORADO DENVER, CO | $2,830,725 | ZRG1 |
| 2019 | Trisomy 21 and RNA polymerase II function1R01HD100935-01 · under RFA-OD-19-016 | BENTLEY, DAVID L | UNIVERSITY OF COLORADO DENVER, CO | $2,828,221 | ZRG1 |
| 2019 | Elevated mitochondrial fusion and function in Down syndrome1R01HD101006-01 · under RFA-OD-19-016 | ROTHERMEL, BEVERLY A | UT SOUTHWESTERN MEDICAL CENTER, TX | $2,021,900 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.